A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-16 and is reviewed periodically as new material appears.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
== Signs and symptoms == Migraines typically present as recurrent, mostly one-sided, pulsating headaches, along with heightened sensitivity to light, sound, and other sensory stimuli. The severity of pain, duration of the headache, and frequency of attacks vary. Symptoms may last for hours or days, seriously affecting quality of life. Migraine attacks can be described in terms of four stages or phases, which may not all be experienced.
Alcohols, including ethanol and 2-propanol/isopropanol are sometimes referred to as surgical spirit. They are used to disinfect the skin before injections, among other uses. Diguanides including chlorhexidine gluconate, a bacteriocidal antiseptic which (with an alcoholic solvent) is considered a safe and effective antiseptic for reducing the risk of infection after clean surgery, including tourniquet-controlled upper limb surgery. It is also used in mouthwashes to treat inflammation of the gums (gingivitis). Polyhexanide (polyhexamethylene biguanide, PHMB) is an antimicrobial compound suitable for clinical use in critically colonized or infected acute and chronic wounds. The physicochemical action on the bacterial envelope prevents or impedes the development of resistant bacterial strains. Iodine, especially in the form of povidone-iodine, is widely used because it is well tolerated; does not negatively affect wound healing; leaves a deposit of active iodine, thereby creating the so-called "remnant", or persistent effect; and has wide scope of antimicrobial activity. The traditional iodine antiseptic is an alcohol solution (called tincture of iodine) or as Lugol's iodine solution. Some studies do not recommend disinfecting minor wounds with iodine because of concern that it may induce scar tissue formation and increase healing time. However, concentrations of 1% iodine or less have not been shown to increase healing time and are not otherwise distinguishable from treatment with saline.
== Illegal importation of ineffective version into the UK == Monovalent mumps vaccine (Mumpsvax) remained available in the US when MMR was introduced in the UK, replacing the MR (measles and rubella) mixed vaccine. No UK-licensed monovalent preparation was ever available. Monovalent mumps vaccines were available before MMR, but only used on a limited scale. This became the subject of considerable argument at the end of the 20th century, since some parents preferred to obtain individually the components of the MMR mixture. One unlicensed mumps vaccine preparation imported into the United Kingdom proved to be essentially ineffective. Immunisation against mumps in the UK became routine in 1988, commencing with MMR. The Aventis-Pasteur "MMR-2" brand is usual in the UK in 2006.
=== Veterinary medicine === DMSO is commonly used in veterinary medicine as a liniment for horses, alone or in combination with other ingredients. In the latter case, often, the intended function of the DMSO is as a solvent, to carry the other ingredients across the skin. Also in horses, DMSO is used intravenously, again alone or in combination with other drugs. It is used alone for the treatment of increased intracranial pressure and/or cerebral edema in horses.
=== P53 and p73 === p53 and p73 are tumor suppressor proteins and their degradation is tightly regulated by ubiquitination. Recently it was shown that their degradation can also occur via an ubiquitin-independent process; NQO1 blocks p53 and p73 degradation in the presence of NADH and protects them from 20S proteasomal degradation. This protein-protein interaction between p53 and NQO1 was non-catalytic.
Sources: en.wikipedia.org
== Properties == An Affibody molecule consists of three alpha helices with 58 amino acids and has a molar mass of about 6 kDa. A monoclonal antibody, for comparison, is 150 kDa, and a single-domain antibody, the smallest type of antigen-binding antibody fragment, 12–15 kDa. Affibody molecules have been shown to withstand high temperatures (90 °C (194 °F)) or acidic and alkaline conditions (pH 2.5 or pH 11, respectively). Affibody molecules have ashort plasma half-life because of their small size.While this is advantageous for imaging,as the unbound tracer is rapidly cleared from the bloodstream, a longer plasma half-life is generally preferred for therapeutic applications. One approach to extend the plasma half-life of small molecules, such as affibody molecules,is to link them to an albumin-binding domain (ABD). A highly effective ABD is the 46-amino acid G148-GA3 domain, which is derived from streptococcal protein G, along with its engineered variant ABD035. This version has a strong femtomolar affinity for human serum albumin (HSA) [28]. The ABD can help prolong the serum half-life by forming a complex with serum albumin (SA) in the bloodstream, increasing the size of the complex and preventing it from being filtered by the kidneys. Binders with an affinity of down to sub-nanomolar have been obtained from native library selections, and binders with picomolar affinity have been obtained following affinity maturation. Affibody molecules conjugated to weak electrophiles bind their targets covalently.
In an organic light-emitting diode (OLED), the electroluminescent material composing the emissive layer of the diode is an organic compound. The organic material is electrically conductive due to the delocalization of pi electrons caused by conjugation over all or part of the molecule, and the material therefore functions as an organic semiconductor. The organic materials can be small organic molecules in a crystalline phase, or polymers. The potential advantages of OLEDs include thin, low-cost displays with a low driving voltage, wide viewing angle, and high contrast and color gamut. Polymer LEDs have the added benefit of printable and flexible displays. OLEDs have been used to make visual displays for portable electronic devices such as cellphones, digital cameras, lighting and televisions.
==== Commander of the Order of the British Empire (CBE) ==== Military Commodore Stephen David Roberts, Royal Navy, C032675H. Brigadier Vivienne Wendy Buck, 539464. Major General Julian Nicholas Edward Buczacki, 547874. Brigadier Matthew Timothy Cansdale, , 542140. Major General Darren Howard Crook, 538948. Colonel Lucy Margaret Giles, 533691. Colonel Michael Robert Smith, 533745. Air Commodore Catherine Clare Coton, Royal Air Force, 8032422G. Air Commodore Jonathan Moreton, Royal Air Force, 2636472F. Air Commodore Gerard Alan Opie, Royal Air Force, 5203734U. Civil Louise Elizabeth Alexander. Human Resources Director, HM Courts and Tribunals Service and Trustee, Rowland Hill Fund. For Public and Voluntary Service. Ellen Atkinson, LVO. Director, Constitution and Major Events, Cabinet Office. For Public Service. Mark Timothy Austin. Partner, Latham & Watkins. For services to the Economy. Henrietta Rosamund Clare Barkworth-Nanton. Co-Founder and Patron, The Joanna Simpson Foundation and Chair, Refuge. For services to People Affected by Domestic Abuse and Homicide. Charlotte Ann Beardmore. Executive Director, Professional Policy, The Society of Radiographers. For services to Radiography. Andrew James Bell. Lately Co-Founder and Chief Executive Officer, AJ Bell plc. For services to the Financial Sector. Professor Michaela Jane Benzeval. Professor of Longitudinal Research and Director of Understanding Society, University of Essex. For services to Social Science. Don Black, OBE. Lyricist. For services to Music. Stuart Christopher John Broad, MBE. Cricketer.
==== RNA sequencing (RNA-seq) ==== Whole transcriptome shotgun sequencing (WTSS) is the latest in gene expression studies, using next generation sequencing (NGS) to quantify RNA in samples on a high throughput scale. As biology trends toward using RNA-seq over microarray analysis in evaluating the transcriptome, so does degradomics. The field adapts the approach to analyzing the presence and quantity of transcripts of proteases, their substrates, and their inhibitors. While developed microarrays remain a major workhorse in studying gene expression in degradomics, its limitations of cross hybridization and dynamic range issues suggest RNA-seq will take a larger role as costs decrease and analysis improves.
Sources: en.wikipedia.org
18 June: The New Zealand Government announces the scrapping of the five-yearly national census. The Māori iwi (tribe) Te Patutokotoko files legal action against Conservation Minister Tama Potaka and the Department of Conservation for not consulting them about granting ten-year concessions to Whakapapa Holdings Limited and Pure Tūroa to run the Tūroa and Whakapapa skifields. New World's Victoria Park supermarket in Auckland is extensively damaged during a major fire. 19 June – The New Zealand Government confirms it suspended NZ$20 million of core sector support funding to the Cook Islands in early June 2025 in retaliation for the Cook Islands government signing a partnership agreement with China without consulting New Zealand, per the requirements of their free association relationship. 20 June Prime Minister Christopher Luxon meets with Chinese President Xi Jinping in Beijing to discuss strengthening bilateral tourism, education and agricultural trade. The New Zealand Symphony Orchestra announces simultaneously the scheduled conclusion of the tenure of Gemma New as its artistic director and principal conductor in 2027, and the appointment of André de Ridder as its new music director, effective in 2027. 21 June – Brian Tamaki's Destiny Church stages a march in Auckland's Aotea Square opposing the spread of non-Christian religions and immigration in New Zealand. Destiny Church's actions are denounced by Minister for Ethnic Communities Mark Mitchell.
== Columns == The columns used in FPLC are large (inner diameters on the order of millimeters) tubes that contain small (micrometer-scale) particles or gel beads as the stationary phase. The chromatographic bed is composed of gel beads inside the column and the sample is introduced into the injector and carried into the column by the flowing solvent. As a result of different components adhering to or diffusing through the gel, the sample mixture gets separated. Columns used with an FPLC can separate macromolecules based on size (size-exclusion chromatography), charge distribution (ion exchange), hydrophobicity, reverse-phase or biorecognition (as with affinity chromatography). For easy use, a wide range of pre-packed columns for techniques such as ion exchange, gel filtration (size exclusion), hydrophobic interaction, and affinity chromatography are available. FPLC differs from HPLC in that the columns used for FPLC can only be used up to maximum pressure of 3-4 MPa (435-580 psi). Thus, if the pressure of HPLC can be limited, each FPLC column may also be used in an HPLC machine.
=== Radioprotectors === A radioprotector is a pharmacon that, when administered, selectively protects healthy cells from the toxic effects of ionizing radiation. The first work with radioprotectors began as part of the Manhattan Project, a military research project to develop and build an atomic bomb.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.